Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT 22 in KRAS-mutant advanced non-small cell lung cancer
NL-OMON55867Phase 3Recruiting
- Sponsor
- NVALT
- Start
- Jun 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing cisplatin + pemetrexed with carboplatin + paclitaxel + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Jun 2016; status: recruiting.
02
Drugs
cisplatinpemetrexedcarboplatinpaclitaxelbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55867.